Lymphoma & Leukemia Access to Care (LyLAC) Study

LyLAC header

Our goal is to learn more about the impact of enhanced support services on patients with blood cancer, including their access to care, quality of life, and financial burden.
Participants will be asked to complete 3 survey questionnaires of approximately 45 minutes each, during a 6-month period, and receive up to $90 total. Additional information and support may be available

Initial survey 1 questionnaire
3-month survey questionnaire
6-month survey questionnaire

Join this study and receive up to $90 by participating!
Who Can Participate?

People who:

  • Are 18 or older
  • Are diagnosed with, or have a recurrence of, leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
  • Are currently receiving primary or relapse treatment for this diagnosis and started within the past 18 months OR are planning to start this treatment within one month, OR Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days
  • Are not currently participating in any Leukemia & Lymphoma Society programs or services
  • Are able to speak English or Spanish
Questions

You will be asked about your:

  • Healthcare experience
  • Health behaviors
  • Mental and physical health
  • Support and health services
  • Financial burden
  • Experiences with cancer
  • Life experiences
Contact Us

To participate in the study or ask questions, contact Dr. Penedo’s team at the Sylvester Comprehensive Cancer Center.

  • Phone Number: (305) 243-8538 / (305) 243-9642
  • E-mail Address: lylac.study@miami.edu
  • Our Location: 1120 NW 14th Street, Miami, FL 33136
Benefits

Your participation will help us learn more about how programs and services can be improved to help patients like you.

About Us

The study is conducted by the University of Miami Sylvester Comprehensive Cancer Center (SCCC), the University of Chicago Comprehensive Cancer Center, and the University of Texas at San Antonio Mays Cancer Center, and is led by Dr. Frank Penedo of SCCC.

This study is funded by The Leukemia & Lymphoma Society.
Top